Newborn screening in Canada - Are we out of step?

Paediatrics and Child Health

Volumn 10, Issue 4, 2005, Pages 203-207

  Hanley, William B ^a  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

Congenital hypothyroidism; Hearing screening; Inherited metabolic disease; Newborn screening; Phenylketonuria; Tandem mass spectrometry

Indexed keywords

CANADA; FOLLOW UP; GENETIC DISORDER; HEALTH CARE ACCESS; HEALTH CARE COST; HUMAN; INFORMED CONSENT; METABOLIC DISORDER; NEWBORN; NEWBORN SCREENING; PROSPECTIVE PAYMENT; REVIEW;

EID: 18944393591     PISSN: 12057088     EISSN: None     Source Type: Journal    
DOI: 10.1093/pch/10.4.203     Document Type: Review

References (33)

1. Guthrie R, Susi A. A simple phenylalanine method for detecting phenylketonuria in large populations of newborn infants. Pediatrics 1963;32:338-43.
2. Dussault JH, Coulombe P, Laberge C, Letarre J, Guyda H, Khoury K. Preliminary report on a mass screening program for neonatal hypothyroidism. J Pediatr 1975;86:670-4.
3. Zytkovicz TH, Fitzgerald EF, Marsdeon G, et al. Tandem mass spectrometric analysis for amino, organic and fatty acid disorders in newborn dried blood spots: A two-year summary from the New England Newborn Screening Program. Clin Chem 2001;47:1945-55.
4. Auray-Blais C, Giguere R, Lemieux B. Newborn urine screening programme in the province of Quebec: An update of 30 years' experience. J Inherit Metab Dis 2003;26:393-402.
5. Dyack S. Expanded newborn screening: Lessons learned from MCAD deficiency. Paediatr Child Health 2004;4:241-3.
6. Fearing MK, Levy HL. Expanded newborn screening using tandem mass spectrometry. Adv Pediatr 2003;50:81-111.
7. Lacey JM, Minutti CZ, Magera MJ, et al. Improved specificity of newborn screening for congenital adrenal hyperplasia by second-tier steroid profiling using tandem mass spectrometry. Clin Chem 2004;50:621-5.
8. Chace DH, DiPerna JC, Naylor EW. Laboratory integration and utilization of tandem mass spectrometry in neonatal screening: A model for clinical mass spectrometry in the next millennium. Acta Paediatr Suppl 1999;88:45-7.
9. Detsky AS, Naylor CD. Canada's health care system - Reform delayed. N Engl J Med 2003;349:804-10.
10. Wilson K. A Canadian agency for public health: Could it work? CMAJ 2004;170:222-3.
11. Canada's Public Health Agency: Bound and gagged? CMAJ 2004;170:1197. (Edit)
12. Bennett C. Building a national public health system. CMAJ 2004;170:1425-6.
13. McCabe LL, Therrell BL Jr, McCabe ER. Newborn screening: Rationale for a comprehensive fully integrated public health system. Mol Genet Metab 2002;77:267-73.
14. National Newborn Screening and Genetics Resource Center (NNSGRC). 〈http://genes-r-us.uthscsa.edu/〉 (Version current at March 10, 2005).
15. National Center for Hearing Assessment & Management. Status of Early Hearing Detection & Intervention in the United States of America. 〈www.infanthearing.org/status/index-html〉 (Version current at March 10, 2005).
16. National Center for Birth Defects and Developmental Disabilities. Newborn Screening for Cystic Fibrosis. 2003. 〈www.cdc.gov/ncbddd/cf/meeting. htm〉 (Version current at March 10, 2005).
17. Comeau AM, Parad RB, Dorkin HL, et al. Population-based newborn screening for genetic disorders when multiple mutation DNA testing is incorporated: A cystic fibrosis newborn screening model demonstrating increased sensitivity but more carrier detection. Pediatrics 2004;113:1573-81.
18. Serving the family from birth to the medical home. A report from the Newborn Screening Task Force convened in Washington DC, May 10-11, 1999. Pediatrics 2000;106:383-427.
19. Pass KA, Lane PA, Fernhoff PM, et al. US newborn screening system guidelines II: Follow-up of children, diagnosis, management, and evaluation. Statement of the Council of Regional Networks for Genetic Services (CORN). J Pediatr 2000;137(Suppl 4):S1-46.
20. United States General Accounting Office Report to Congressional Requesters. Newborn screening: Characteristics of state programs. 〈www.gao.gov/cgi-bin/getrpt?GAO-03-449.7〉 (Version current at March 10, 2005).
21. American Academy of Pediatrics, Committee on Nutrition. Reimbursement for medical foods for special dietary use. Pediatrics 2003;111:1117-9.
22. Liebl B, Nennstiel-Ratzel U, von Kries R, et al. Very high compliance in an expanded MS-MS-based newborn screening program despite written parental consent. Prev Med 2002;34:127-31.
23. Dionisi-Vici C, Rizzo C, Burlina AB, et al. Inborn errors of metabolism in the Italian pediatric population: A national retrospective survey. J Pediatr 2002;140:321-7.
24. Insinga RP, Laessig RH, Hoffman GL. Newborn screening with tandem mass spectrometry: examining its cost-effectiveness in the Wisconsin Newborn Screening Panel. J Pediatr 2002;141:524-31. (Erratum in 2003;142:56)
25. Schoen EJ, Baker JC, Colby CJ, To TT. Cost-benefit analysis of universal tandem mass spectrometry for newborn screening. Pediatrics 2002;110:781-876.
26. Venditti LN, Venditti CP, Berry GT, et al. Newborn screening by tandem mass spectrometry for medium-chain Acyl-CoA dehydrogenase deficiency: a cost-effectiveness analysis. Pediatrics 2003;112:1005-15.
27. Schulze A, Lindner M, Kohlmuller D, et al. Expanded newborn screening for inborn errors of metabolism by electrospray ionization-tandem mass spectrometry: Results, outcome and implications. Pediatrics 2003;111:1399-406.
28. Waisbren SE, Albers S, Amato S, et al. Effect of expanded newborn screening for biochemical genetic disorders on child outcomes and parental stress. JAMA 2003;290:2564-72.
29. Chace DH, Sherwin JE, Hillman SL, Lorey F, Cunningham GC. Use of phenylalanine-to-tyrosine ratio determined by tandem mass spectrometry to improve newborn screening for phenylketonuria of early discharge specimens collected in the first 24 hours. Clin Chem 1998;44:2405-9.
30. Seymor CA, Cockburm F, Thomason MJ, et al. Newborn screening for inborn errors of metabolism: A systemic review. Health Technol Assess 1997;1(11):1-95.
31. Pollitt RJ, Leonard JV, Green A, et al. Neonatal screening for inborn errors of metabolism: Cost, yield and outcome. Health Technol Assess 1997;1(7):1-202.
32. Walter JH. Arguments for early screening: A clinician's perspective. Eur J Pediatr 2003;162(Suppl 1):S2-4.
33. Honeycutt A, Dunlap L, Chen H, al Homsi G, Grosse S, Schendel D. Economic costs associated with mental retardation, cerebral palsy, hearing loss and visual impairment - United States, 2003. MMWR 2004;53:57-9.